J Med Chem. 2018 Jun 28;61(12):5412-5423. doi: 10.1021/acs.jmedchem.8b00733. Epub 2018 Jun 18.
NLRP3 inflammasome plays critical roles in a variety of human diseases and represents a promising drug target. In this study, we established the in vivo functional activities of JC124, a previously identified NLRP3 inflammasome inhibitor from our group, in mouse models of Alzheimer's disease and acute myocardial infarction. To understand the chemical space of this lead structure, a series of analogues were designed, synthesized, and biologically characterized. The results revealed the critical roles of the two substituents on the benzamide moiety of JC124. On the other hand, modifications on the sulfonamide moiety of JC124 are well tolerated. Two new lead compounds, 14 and 17, were identified with improved inhibitory potency (IC values of 0.55 ± 0.091 and 0.42 ± 0.080 μM, respectively). Further characterization confirmed their selectivity and in vivo target engagement. Collectively, the results strongly encourage further development of more potent analogues based on this chemical scaffold.
NLRP3 炎性小体在多种人类疾病中发挥着关键作用,是一个很有前途的药物靶点。在这项研究中,我们在阿尔茨海默病和急性心肌梗死的小鼠模型中建立了我们之前从我们的团队中鉴定出的 NLRP3 炎性小体抑制剂 JC124 的体内功能活性。为了了解该先导结构的化学空间,设计、合成并对一系列类似物进行了生物学特征分析。结果揭示了 JC124 苯甲酰胺部分的两个取代基的关键作用。另一方面,JC124 磺酰胺部分的修饰是可以耐受的。发现了两种新的先导化合物 14 和 17,它们具有改善的抑制活性(IC 值分别为 0.55±0.091 和 0.42±0.080 μM)。进一步的特性分析证实了它们的选择性和体内靶标结合。总的来说,这些结果强烈鼓励基于该化学结构进一步开发更有效的类似物。